Dow Up0.76% Nasdaq Up0.69%

Sinovac Biotech Ltd. (SVA)

5.40 Up 0.03(0.56%) Oct 24, 4:00PM EDT
ProfileGet Profile for:
Sinovac Biotech Ltd.
No. 39 Shangdi Xi Road
Haidian District
Beijing, 100085
China - Map
Phone: 86 10 8289 0088
Fax: 86 10 6296 6910

Index Membership:N/A
Full Time Employees:715

Business Summary 

Sinovac Biotech Ltd., a biopharmaceutical company, is engaged in the research, development, manufacture, and commercialization of vaccines for hepatitis A, hepatitis B, and influenza viruses in the People's Republic of China. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine; split viron pandemic influenza vaccine; and RabEnd, an animal rabies vaccine. The company has also completed a phase I clinical trial of a SARS vaccine, as well as develops the EV71 vaccine, which has completed phase III clinical trial. Further, it develops a pipeline of vaccine candidates in the clinical and pre-clinical development phases, including human vaccines for pneumococcal, rabies, varicella, and rubella that are in pre-clinical stage. The company has a collaboration agreement with Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and a license agreement with Medimmune, LLC to use patented reverse genetics technology pertaining to virus strain production for vaccines, including the H5N1 influenza virus strain. Sinovac Biotech Ltd. was founded in 1999 and is headquartered in Beijing, the People's Republic of China.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Sinovac Biotech Ltd.

Key Executives 
Mr. Ming Xia , 40
VP of Sales & Marketing
Dr. Wei dong Yin , 49
Chairman, Chief Exec. Officer, Pres, Managing Director, Sec., Chairman of Sinovac Hong Kong, Chairman of Tangshan Yian, Chairman of Sinovac Dalian and Director of Sinovac Biotech Co
Ms. Nan Wang , 48
Chief Financial Officer and VP of Bus. Devel.
Mr. Zhenshan Zhang , 39
Gen. Mang. of Tangshan Y├Čan
Mr. Helen G. Yang ,
Mang. of International Bus. Devel.
Amounts are as of Dec 31, 2006 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.